Northeast Investment Management Sells 4,473 Shares of Johnson & Johnson (NYSE:JNJ)

Northeast Investment Management trimmed its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 175,956 shares of the company's stock after selling 4,473 shares during the period. Johnson & Johnson accounts for about 1.4% of Northeast Investment Management's portfolio, making the stock its 24th biggest holding. Northeast Investment Management's holdings in Johnson & Johnson were worth $29,181,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Tallon Kerry Patrick bought a new stake in Johnson & Johnson in the 4th quarter valued at $290,000. Capital & Planning LLC lifted its holdings in shares of Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock worth $221,000 after buying an additional 183 shares in the last quarter. Brighton Jones LLC boosted its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. Union Bancaire Privee UBP SA acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at about $85,886,000. Finally, Apollon Wealth Management LLC raised its stake in Johnson & Johnson by 20.7% in the 4th quarter. Apollon Wealth Management LLC now owns 105,500 shares of the company's stock worth $15,257,000 after purchasing an additional 18,082 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ traded up $0.12 during trading hours on Friday, reaching $156.78. The stock had a trading volume of 3,832,090 shares, compared to its average volume of 7,933,013. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market capitalization of $377.23 billion, a PE ratio of 23.57, a PEG ratio of 2.56 and a beta of 0.42. The company's 50-day moving average is $153.69 and its two-hundred day moving average is $153.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.32%. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Morgan Stanley raised their price target on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.